PAR-24-029: Planning for Product Development Strategy (R34 Clinical Trial Not Allowed)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2023.
National Institutes of Health offered grants of up to $225,000 to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on December 29, 2024.
From the official notice on Grants.gov, last changed December 30, 2024. Checked November 7, 2026.
- Award ceiling$225,000
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeR34
- Clinical trialsNot allowed
- Funded byNIAID
- Median yearly award$301,247
- Typical project length1 year
- R34, Planning Grant. Planning a clinical trial: design, protocol and feasibility work before the trial itself. Other open R34 notices.
Projects funded under PAR-24-029 were run by National Institute of Allergy and Infectious Diseases (NIAID, 2 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read PAR-24-029 in the NIH Guide.
Other notices with this title
| Notice | Posted | Deadline | Status |
|---|---|---|---|
| PAR-25-099 | December 30, 2024 | Closed February 19, 2026 | Closed |
Key dates
| Posted | August 14, 2023 |
|---|---|
| Deadline | December 29, 2024 |
| Archived by Grants.gov | January 28, 2025 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Is this a realistic fit?
- Projects NIH funded under this notice had a median yearly award of $301,247; it allows up to $225,000 per award.
- Most of the program's money (67% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
The purpose of this Notice of Funding Opportunity (NOFO) is to support the development of a comprehensive and well-defined product development strategy for next-generation treatments for HIV and HIV-associated comorbidities, coinfections and complication and preventive strategies for HIV, as well as facilitating the translation of research findings into drug products that enables submission of an Investigational New Drug (IND) application to the FDA.
Funded under PAR-24-029 so far
NIH funded 2 projects under PAR-24-029 in fiscal 2025, at 2 institutions. The median yearly award was $301,247.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Hematopoietic Stem/Progenitor Cell-Based Chimeric Antigen Receptor Gene Therapy for HIV Infection | University of California Los Angeles | 2025 | $343,744 |
| A development strategy to obtain IND approval of HBVZ10, a new HBV cure therapy candidate | Hbvtech | 2025 | $258,750 |
Who has won Allergy and Infectious Diseases Research grants before
From fiscal 2021 to 2025, Allergy and Infectious Diseases Research (93.855) awarded $22 billion across 13,282 grant awards, an average of $1.6 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Fred Hutchinson Cancer Center | Washington | 85 | $938 million |
| Duke University | North Carolina | 230 | $781 million |
| University of California, Los Angeles | California | 138 | $745 million |
| The Johns Hopkins University | Maryland | 321 | $668 million |
| Emory University | Georgia | 282 | $650 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is PAR-24-029 still open?
No. It closed on December 29, 2024.
Who can apply for Planning for Product Development Strategy (R34 Clinical Trial Not Allowed)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Planning for Product Development Strategy (R34 Clinical Trial Not Allowed)?
Closed December 29, 2024. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $225,000 each.
Who has been funded under PAR-24-029?
NIH RePORTER lists 2 projects funded under PAR-24-029 in fiscal 2025, at 2 institutions. The most were at University of California Los Angeles, Hbvtech.
Who has won Allergy and Infectious Diseases Research grants before?
The largest recipients over five fiscal years were Fred Hutchinson Cancer Center, Duke University, University of California, Los Angeles. The program made 13,282 awards worth $22 billion in that time.
Similar open grants
- Feasibility Clinical Trials of Mind and Body Interventions for NCCIH High Priority Research Topics (R34 Clinical Trial Required)
- Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R34 Clinical Trial Optional)
- Intervention Research to Improve Native American Health (R34 Clinical Trial Optional)
- Innovative Research to Improve Native Hawaiian and Pacific Islander (NHPI) Health Outcomes (R34 - Clinical Trial Optional)
- NHLBI Clinical Trial Pilot Studies (R34 Clinical Trial Optional)
- Change of Recipient Organization (Type 7 Parent Clinical Trial Optional)